Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy.
Hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States. It recurs universally after transplant but the rate of fibrosis and the development of graft failure is variable. Different donor and recipient features have been demonstrated to impact fibrosis. Plasma cell hepatitis, a histologic finding, is one feature associated with poor graft and patient outcomes. The pathogenic mechanism resulting in plasma cell hepatitis is poorly understood, with evidence suggesting a role for both the HCV and the immune system.A recent publication described plasma cell hepatitis in a larger context of immune medicated graft dysfunction in transplant recipients receiving interferon based therapy. This manuscript will highlight the topic of plasma cell hepatitis and provide commentary on the lack of recognition, the data regarding pathophysiologic mechanisms and the potential management options.
Section of Hepatology, Loyola University Medical Center, Maywood, IL 60153, United States. ekallwitz@lumc.edu
Eric R
ER
Kallwitz
D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D055031:Primary Graft Dysfunction / Q000209:etiology*
D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols
Biopsy; Hepatitis C virus; Plasma cells; Sustained virological response